219 related articles for article (PubMed ID: 21321299)
1. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.
van Kampen RJ; Canals C; Schouten HC; Nagler A; Thomson KJ; Vernant JP; Buzyn A; Boogaerts MA; Luan JJ; Maury S; Milpied NJ; Jouet JP; Ossenkoppele GJ; Sureda A
J Clin Oncol; 2011 Apr; 29(10):1342-8. PubMed ID: 21321299
[TBL] [Abstract][Full Text] [Related]
2. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
4. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
[TBL] [Abstract][Full Text] [Related]
5. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation.
Ferrara F; Viola A; Copia C; Schiavone EM; Celentano M; Pollio F; D'Amico MR; Palmieri S
Hematol Oncol; 2006 Jun; 24(2):73-7. PubMed ID: 16550628
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
[TBL] [Abstract][Full Text] [Related]
8. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Kyriakou C; Canals C; Sibon D; Cahn JY; Kazmi M; Arcese W; Kolbe K; Gorin NC; Thomson K; Milpied N; Niederwieser D; Indrák K; Corradini P; Sureda A; Schmitz N
J Clin Oncol; 2010 May; 28(13):2227-32. PubMed ID: 20368570
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study.
Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S
Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
12. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
[TBL] [Abstract][Full Text] [Related]
14. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
16. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
17. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry.
Jantunen E; Canals C; Rambaldi A; Ossenkoppele G; Allione B; Blaise D; Conde E; Tilly H; Cook G; Clark F; Gallamini A; Haynes A; Mounier N; Dreger P; Pfreundschuh M; Sureda A;
Haematologica; 2008 Dec; 93(12):1837-42. PubMed ID: 18838474
[TBL] [Abstract][Full Text] [Related]
20. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ
Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
